OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Research Point Global and WuXi Clinical Development Services have revealed that they are to combine and rebrand as a new CRO, WuXi Clinical.
Research Point Global and WuXi Clinical Development Services (CDS) have revealed that they are to combine and rebrand as a new contract research organization (CRO), WuXi Clinical.
The rebranded CRO will be launched during DIA 2019, which will be held June 23–27, 2019 in San Diego, CA, and is set to specialize in collaborative partnering for global clinical trials. The combined offering will focus on enlarging opportunities across small to mid-tier clients and will feature expanded capabilities to provide further benefits to clients as a gateway partner into the clinical trial space in China.
“Our goal as WuXi Clinical is to continue to work with our client partners to be greater than the sum of our parts,” commented Becky Carpenter, head of North America/Euro Operations at WuXi Clinical. “In fact, our new company strategy is entirely focused around how we can work ‘better together’.”
“This is a hugely exciting time for WuXi Clinical as we bring together our focus on providing a very collaborative customer approach, coupled with additional resources. Our targets for this year are to cement our offering amongst mid-tier pharma, and we anticipate good traction in the market,” added Johnathan Lee, general manager and head of WuXi Clinical. “With our combined capabilities, we now have a crucial role to play in maximizing new opportunities and working as a bridge between R&D markets in the US and China.”
Source: WuXi Clinical